WO2013164512A3 - Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular - Google Patents

Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular Download PDF

Info

Publication number
WO2013164512A3
WO2013164512A3 PCT/ES2013/070279 ES2013070279W WO2013164512A3 WO 2013164512 A3 WO2013164512 A3 WO 2013164512A3 ES 2013070279 W ES2013070279 W ES 2013070279W WO 2013164512 A3 WO2013164512 A3 WO 2013164512A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
prevention
treatment
oxidative stress
neovascularization
Prior art date
Application number
PCT/ES2013/070279
Other languages
English (en)
French (fr)
Other versions
WO2013164512A2 (es
Inventor
María Jesús GONZÁLEZ GARCÍA
Margarita Calonge Cano
Amalia ENRÍQUEZ DE SALAMANCA ALADRO
Michael E. Stern
Antonio ABENGÓZAR VELA
Original Assignee
Universidad De Valladolid
Allergan Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Valladolid, Allergan Inc. filed Critical Universidad De Valladolid
Publication of WO2013164512A2 publication Critical patent/WO2013164512A2/es
Publication of WO2013164512A3 publication Critical patent/WO2013164512A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005—Other compounding ingredients characterised by their effect
    • C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/261—Alcohols; Phenols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22—Organic compounds
    • C11D7/26—Organic compounds containing oxygen
    • C11D7/267—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de la quercetina (QCT) o de una composición que comprende QCT y al menos otro compuesto polifenólico, preferiblemente resveratrol (RES), para el tratamiento y/o prevención de lesiones o enfermedades que cursan con inflamación, estrés oxidativo y/o neovascularización ocular, preferiblemente del segmento anterior, más preferiblemente de la superficie ocular y aun más preferiblemente del epitelio corneal. La invención también se refiere al uso de la QCT y de dicha composición como agente antimicrobiano, antioxidante y antiinflamatorio en soluciones de limpieza y mantenimiento de lentes de contacto.
PCT/ES2013/070279 2012-05-04 2013-05-06 Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular WO2013164512A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201230664 2012-05-04
ES201230664A ES2428665B1 (es) 2012-05-04 2012-05-04 Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular

Publications (2)

Publication Number Publication Date
WO2013164512A2 WO2013164512A2 (es) 2013-11-07
WO2013164512A3 true WO2013164512A3 (es) 2014-03-20

Family

ID=48700616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2013/070279 WO2013164512A2 (es) 2012-05-04 2013-05-06 Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular

Country Status (2)

Country Link
ES (1) ES2428665B1 (es)
WO (1) WO2013164512A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729862T3 (es) 2014-03-28 2019-11-06 Hortus Novus Srl Composiciones basadas en azafrán para la prevención y/o el tratamiento de trastornos oculares degenerativos
US10092585B2 (en) 2014-09-19 2018-10-09 Hortus Novus Srl Compositions based on saffron for the prevention and/or treatment of corneal dystrophies
IT202200002108A1 (it) 2022-02-07 2023-08-07 Indena Spa Composizioni a base di quercetina per il trattamento e la prevenzione di affezioni oculari

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057473A1 (en) * 2001-01-17 2002-07-25 Young-Mee Park Method for inhibiting vegf and epo gene expression by quercetin
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
WO2004062683A1 (en) * 2003-01-09 2004-07-29 Michael Donald Farley Improvements in or relating to immune functions
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
US20050220907A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Implanted medical devices with anti-inflammatory coatings
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
EP1844784A1 (en) * 2006-03-28 2007-10-17 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
WO2008016095A1 (fr) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008061536A1 (en) * 2006-11-22 2008-05-29 Ocumedic Aps Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
WO2011057183A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057473A1 (en) * 2001-01-17 2002-07-25 Young-Mee Park Method for inhibiting vegf and epo gene expression by quercetin
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
WO2004062683A1 (en) * 2003-01-09 2004-07-29 Michael Donald Farley Improvements in or relating to immune functions
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
US20050220907A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Implanted medical devices with anti-inflammatory coatings
EP1844784A1 (en) * 2006-03-28 2007-10-17 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
WO2008016095A1 (fr) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
WO2008061536A1 (en) * 2006-11-22 2008-05-29 Ocumedic Aps Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
WO2011057183A1 (en) * 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CAO X ET AL: "The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 91, no. 1, 1 July 2010 (2010-07-01), pages 15 - 25, XP027063939, ISSN: 0014-4835, [retrieved on 20100528], DOI: 10.1016/J.EXER.2010.03.016 *
HAYNES W L ET AL: "EFFECT OF INHIBITORS OF ARACHIDONIC ACID METABOLISM ON CORNEAL NEOVASCULARIZATION IN THE RAT", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE - IOVS, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 30, no. 7, 1 July 1989 (1989-07-01), pages 1588 - 1593, XP009052446, ISSN: 0146-0404 *
JIN SOOK YOON ET AL: "Quercetin Inhibits IL-1[beta]-Induced Inflammation, Hyaluronan Production and Adipogenesis in Orbital Fibroblasts from Graves' Orbitopathy", PLOS ONE, vol. 6, no. 10, 19 October 2011 (2011-10-19), pages e26261, XP055077146, DOI: 10.1371/journal.pone.0026261 *
KELLY G S: "Quercetin", ALTERNATIVE MEDICINE REVIEW, THORNE RESEARCH INC., SANDPOINT, US, vol. 16, no. 2, 1 June 2011 (2011-06-01), pages 172 - 194, XP008164453, ISSN: 1089-5159 *
MILAN STEFEK ET AL: "Eye Lens in Aging and Diabetes: Effect of Quercetin", REJUVENATION RESEARCH, vol. 14, no. 5, 1 October 2011 (2011-10-01), pages 525 - 534, XP055077137, ISSN: 1549-1684, DOI: 10.1089/rej.2011.1170 *
NIINA M M SAVIRANTA ET AL: "Plant flavonol quercetin and isoflavone biochanin A differentially induce protection against oxidative stress and inflammation in ARPE-19 cells", FOOD RESEARCH INTERNATIONAL, ELSEVIER APPLIED SCIENCE, BARKING, GB, vol. 44, no. 1, 31 October 2010 (2010-10-31), pages 109 - 113, XP028134769, ISSN: 0963-9969, [retrieved on 20101104], DOI: 10.1016/J.FOODRES.2010.10.056 *
ROMERO J ET AL: "Pharmacologic modulation of acute ocular inflammation with quercetin", OPHTHALMIC RESEARCH, S. KARSER AG. BASEL, CH, vol. 21, 1 January 1989 (1989-01-01), pages 112 - 117, XP002113010, ISSN: 0030-3747 *
SOUMYAJIT MAJUMDAR ET AL: "Potential of the bioflavonoids in the prevention/treatment of ocular disorders", JOURNAL OF PHARMACY AND PHARMACOLOGY, 1 January 2010 (2010-01-01), pages 951 - 965, XP055077194, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1211/jpp.62.08.0001/pdf> [retrieved on 20130830], DOI: 10.1211/jpp.62.08.0001 *

Also Published As

Publication number Publication date
ES2428665A1 (es) 2013-11-08
WO2013164512A2 (es) 2013-11-07
ES2428665B1 (es) 2014-10-01

Similar Documents

Publication Publication Date Title
MY171920A (en) Prevention and treatment of ocular conditions
MY183449A (en) Formulations of quinones for the treatment of ophthalmic diseases
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
WO2012103186A3 (en) Androgen composition for treating an opthalmic condition
MX2011011310A (es) Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas.
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
WO2013180834A3 (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
WO2011076368A3 (en) Topical ophthalmic peptide formulation
WO2013164512A3 (es) Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EA035539B9 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
WO2014142469A3 (ko) 안과 염증 질환 치료용 점안제 조성물 및 이의 제조 방법
MX350201B (es) Composiciones oftalmicas con ceras alcoxiladas naturales.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13732205

Country of ref document: EP

Kind code of ref document: A2